| Dr Lauren Kelly Macafee, MD | |
|
111 Colchester Ave, University Of Vermont Medical Center, Burlington, VT 05401-1473 | |
| (802) 847-1400 | |
| (802) 847-8433 |
| Full Name | Dr Lauren Kelly Macafee |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629392600 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
A new robot using high-precision tactile sensors and flexible motor control technology has taken Japan one step closer to its goal of providing high-quality care for its growing elderly population.
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.
Since the introduction of the Affordable Care Act, which provided access to health insurance to millions of previously uninsured adults in the United States, the availability of appointments with primary care physicians has improved for patients with Medicaid and remains unchanged for patients with private coverage, according to new research led by the Perelman School of Medicine and the Leonard Davis Institute of Health Economics at the University of Pennsylvania.
› Verified 6 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
A new robot using high-precision tactile sensors and flexible motor control technology has taken Japan one step closer to its goal of providing high-quality care for its growing elderly population.
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.
Since the introduction of the Affordable Care Act, which provided access to health insurance to millions of previously uninsured adults in the United States, the availability of appointments with primary care physicians has improved for patients with Medicaid and remains unchanged for patients with private coverage, according to new research led by the Perelman School of Medicine and the Leonard Davis Institute of Health Economics at the University of Pennsylvania.
› Verified 6 days ago
| Entity Name | Planned Parenthood Of Northern New England, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578529350 PECOS PAC ID: 8729069505 Enrollment ID: O20040527000305 |
News Archive
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
A new robot using high-precision tactile sensors and flexible motor control technology has taken Japan one step closer to its goal of providing high-quality care for its growing elderly population.
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.
Since the introduction of the Affordable Care Act, which provided access to health insurance to millions of previously uninsured adults in the United States, the availability of appointments with primary care physicians has improved for patients with Medicaid and remains unchanged for patients with private coverage, according to new research led by the Perelman School of Medicine and the Leonard Davis Institute of Health Economics at the University of Pennsylvania.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lauren Kelly Macafee, MD 111 Colchester Ave, University Of Vermont Medical Center, Burlington, VT 05401-1473 Ph: (802) 847-1400 | Dr Lauren Kelly Macafee, MD 111 Colchester Ave, University Of Vermont Medical Center, Burlington, VT 05401-1473 Ph: (802) 847-1400 |
News Archive
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
A new robot using high-precision tactile sensors and flexible motor control technology has taken Japan one step closer to its goal of providing high-quality care for its growing elderly population.
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.
Since the introduction of the Affordable Care Act, which provided access to health insurance to millions of previously uninsured adults in the United States, the availability of appointments with primary care physicians has improved for patients with Medicaid and remains unchanged for patients with private coverage, according to new research led by the Perelman School of Medicine and the Leonard Davis Institute of Health Economics at the University of Pennsylvania.
› Verified 6 days ago
Dr. Ira Mark Bernstein, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Department Of Obstetrics And Gynceology, Burlington, VT 05401 Phone: 802-847-5066 Fax: 802-847-2772 | |
Dr. Eleanor Lacava Capeless, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fahc, Acc 4th Floor, Burlington, VT 05401 Phone: 802-847-5066 | |
Dr. Renju S Raj, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-3450 | |
Charles Warner Ashley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-5110 | |
Dr. Alexandra Charlotte Fenton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 96 Colchester Ave, Burlington, VT 05401 Phone: 802-658-0505 | |
Justin A. Deangelis, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-1400 Fax: 802-847-8433 | |
Dr. Adam Buckley, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-8181 |